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CLINICAL ARTICLE
Decompressive craniectomy (DC) is a well-estab-lished neurosurgical procedure in the treatment of refractory intracranial hypertension. Although 
DC is highly effective and generally regarded as a life-
saving procedure, it remains an invasive surgery with an 
elevated risk for complications.18 To restore the bony cov-
erage of the brain and avoid clinical impairments like the 
“syndrome of the trephined,”3 DC is usually followed by 
a second surgery to cover the defect once the brain swell-
ing has regressed. Many options exist as to the timing and 
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SUBMITTED November 29, 2017. ACCEPTED June 11, 2018.
INCLUDE WHEN CITING Published online November 23, 2018; DOI: 10.3171/2018.6.JNS172605.
* A.S. and M.M. contributed equally to this work and share first authorship.
ACE-inhibitors: a preventive measure for bone flap 
resorption after autologous cranioplasty?
*Alessa Schütz, MD,1 Michael Murek, MD,1 Lennart Henning Stieglitz, MD,2  
Corrado Bernasconi, MD, PhD,3 Sonja Vulcu, MD,1 Jürgen Beck, MD,1 Andreas Raabe, MD,1 and 
Philippe Schucht, MD1
Departments of 1Neurosurgery and 3Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland; and 
2Department of Neurosurgery, Zurich University Hospital, Zurich, Switzerland
OBJECTIVE Decompressive craniectomy (DC) is an established treatment for refractory intracranial hypertension. It is 
usually followed by autologous cranioplasty (AC), the reinsertion of a patient’s explanted bone flap. A frequent long-term 
complication of AC is bone flap resorption (BFR), which results in disfigurement as well as loss of the protective covering 
of the brain. This study investigates risk factors for BFR after AC, including medical conditions and antihypertensive drug 
therapies, with a focus on angiotensin-converting enzyme inhibitors (ACEIs), which have been associated with a benefi-
cial effect on bone healing and bone preservation in orthopedic, osteoporosis, and endocrinology research.
METHODS In this single-center, retrospective study 183 consecutive cases were evaluated for bone flap resorption 
after AC. Information on patient demographics, medical conditions, antihypertensive therapy, and BFR—defined as an 
indication for revision surgery established by a neurosurgeon based on clinical or radiographic assessments—was col-
lected. A Kaplan-Meier analysis of time from AC to diagnosis of BFR was performed, and factors associated with BFR 
were investigated using the log-rank test and Cox regression.
RESULTS A total of 158 patients were considered eligible for inclusion in the data analysis. The median follow-up time 
for this group was 2.2 years (95% CI 1.9–2.5 years). BFR occurred in 47 patients (29.7%), with a median time to event 
of 3.7 years (95% CI 3.3–4.1 years). An ACEI prescription was recorded in 57 cases (36.1%). Univariate Kaplan-Meier 
analysis and the log-rank test revealed that ACEI therapy (2-year event free probability [EFP] 83.8% ± 6.1% standard er-
ror vs 63.9% ± 5.6%, p = 0.02) and ventriculoperitoneal (VP) shunt treatment (2-year EFP 86.9% ± 7.1% vs 66% ± 5.0%, 
p = 0.024) were associated with a lower probability of BFR. Multiple Cox regression analysis showed ACEI therapy (HR 
0.29, p = 0.012), VP shunt treatment (HR 0.278, p = 0.009), and male sex (HR 0.500, p = 0.040) to be associated with a 
lower risk for BFR, whereas bone fragmentation (HR 1.92, p = 0.031) was associated with a higher risk for BFR.
CONCLUSIONS Hypertensive patients treated with ACEIs demonstrate a lower rate of BFR than patients treated with 
other hypertensive medications and nonhypertensive patients. Our results are in line with previous reports on the posi-
tive influence of ACEIs on bone healing and preservation. Further analysis of the association between ACEI treatment 
and BFR development is needed and will be evaluated in a multicenter prospective trial.
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procedure for covering the bony defect,10,27 but autologous 
cranioplasty (AC)—the reinsertion of the explanted, cryo-
conserved bone flap—is the most common one.10
A frequently observed long-term complication of 
AC is bone flap resorption (BFR), an aseptic, osteolytic 
process leading to significant disintegration of the reim-
planted bone in up to 54.4% of pediatric patients4,21,25 and 
up to 30.4% of patients in mixed cohorts.5,8,9,17,22,35 BFR 
can lead to visible and palpable, aesthetically disfigur-
ing defects, and in its advanced form it results in a loss 
of the bony coverage of the brain. Revision surgery with 
implantation of a synthetic bone flap is required in severe 
cases of BFR.
In recent decades there has been a growing interest 
in identification of potential strategies for lowering BFR 
rates, avoiding revision surgery, and preventing possible 
surgical complications. Previous studies have found risk 
factors such as fragmentation of the bone flap,5,8, 21,33 
younger age,4,5,8,21 longer time between DC and AC,5,33 
ventriculoperitoneal (VP) shunt implantation,4,22 and larg-
er bone flap size32 to be associated with higher rates of 
BFR. The pathophysiological mechanism of BFR, how-
ever, remains unclear, and no preventive measures have 
been identified to date.
In addition, research in the fields of orthopedics, osteo-
porosis, and endocrinology has identified a beneficial ef-
fect of angiotensin-converting enzyme inhibitors (ACEIs) 
on bone preservation and bone healing. These medica-
tions have been found to be associated with an increased 
bone mineral density,26 improved osteoporosis,34 and bone 
healing,39 as well as reduced fracture risk.28,31 They pre-
vent the conversion of angiotensin I into angiotensin II, 
which increases calcium metabolism and activates osteo-
clasts responsible for bone resorption.34 To verify whether 
these findings could be applied to autologous bone flaps 
we set out to investigate a putative effect of ACEIs on BFR 
development.
Methods
Study Design and Patient Cohort
We performed a single-center, retrospective analysis 
of 183 consecutive cases in which patients received AC 
after DC at the Department of Neurosurgery, Inselspital, 
University Hospital Bern, Switzerland, between June 2003 
and August 2015. Data were collected and managed us-
ing REDCap, a secure, web-based electronic data capture 
tool15 in a retrospective review of hospital records and CT 
scans. Patients with DC, followed by primary implanta-
tion of the autologous bone flap (AC) were included in the 
study. Patients who did not show up for at least 1 follow-up 
visit or never received a follow-up CT scan were consid-
ered ineligible and were excluded from the analysis. Sub-
jects who received a synthetic bone flap within 1 year after 
AC for reasons other than BFR were also excluded from 
the study.
Institutional protocol required a postoperative follow-
up visit with CT scan 6 weeks after surgery. Further 
follow-up visits were scheduled depending on the clini-
cal or radiographic findings of the initial follow-up or if 
requested by the patient or his or her family practitioner. 
The last point of follow-up was defined as the date of BFR 
diagnosis by clinical or radiographic examination. For pa-
tients with no documented BFR, the clinical results of the 
most recent follow-up visit or available CT scan defined 
the follow-up time.
Definition of Bone Flap Resorption
Bone flap resorption (BFR) was defined at the point of 
necessity of surgical revision, as diagnosed after a clinical 
examination or viewing of CT scans by the treating neu-
rosurgeon (Fig. 1).
Bone flap size was estimated using the maximum an-
teroposterior (B) and craniocaudal diameters (b) from lat-
eral scout images with the formula A = p/4 × B × b, as 
proposed by Dünisch et al.8 and Ewald et al.9
Decompressive Craniectomy
DC was performed according to a previously published 
protocol14 with the cross midline skin incision technique 
to facilitate cranioplasty and a DC diameter of at least 150 
mm. The dura was opened in a stellate form, folded back 
on the exposed brain, and covered with a layer of Surgicel 
(Ethicon, Inc.). The explanted, sterile bone flap was cryo-
conserved at -80°C.
Autologous Cranioplasty
The sterile, cryoconserved bone flaps were thawed for 
reimplantation at room temperature. In 21 (13.3%) patients 
multiple 1-mm–diameter holes were drilled into the bone 
flap in order to prevent the build-up of epidural fluid col-
lections in combination with a subcutaneous drainage. 
The number of holes drilled was determined according to 
the individual neurosurgeon’s preference and ranged be-
tween 3 and 52 per bone flap (mean 8 holes). Meticulous 
dissection of the myocutaneous flap and exposure of bony 
margins followed. The bone flap fixation method—i.e., ti-
tanium plates and screws (low profile, Synthes), titanium 
clamps (Craniofix, Braun Medical AG), or cranial sutures 
(nonabsorbable Surgilon braided nylon, Covidien)—was 
based on the neurosurgeon’s preference.
Recorded Variables
The following variables were extracted from clinical 
FIG. 1. Left: CT scan showing BFR 4.9 years after bone flap reimplanta-
tion. Right: 3D CT reconstruction of skull with BFR (same case).
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records and entered into our database: patient sex, age, ad-
mission diagnosis leading to DC, dates of surgery (includ-
ing DC and AC), number of bone fragments and size, VP 
shunt placement, diagnosis of arterial hypertension and 
diabetes, nicotine consumption, antihypertensive therapy 
with ACEIs, and the date of the last follow-up visit. The 
presence of BFR was documented in clinical records based 
on clinical evaluation or after evaluation of CT scans.
Patients who declined revision surgery despite an indi-
cation as determined by the treating neurosurgeon were 
included in the study and categorized as patients with 
BFR.
Statistical Analysis
Baseline characteristics of patients with and without 
BFR were analyzed descriptively and compared using 
the 2-sample t-test with pooled variances for continuous 
variables and Fisher’s exact test for categorical variables. 
A Kaplan-Meier analysis of time from AC to diagnosis 
of BFR was performed and putative predictors associated 
with BFR were investigated using the log-rank test. A 
multivariable Cox proportional hazards model was fitted 
to delineate the specific influence of ACEI on BFR after 
accounting for previously mentioned predictors. Median 
follow-up time and results in the time-to-event analysis 
were presented and compared as median time-to-event 
(mTTE) calculated using the reversed Kaplan-Meier es-
timate30 and 2-year event-free probabilities (EFPs). Re-
sults from Cox regression analysis were presented with 
hazard ratios (HRs) and 95% confidence intervals (CIs). 
Patients missing data on any of the predictors and pa-
tients without follow-up were excluded from the analysis. 
To avoid unnecessary radiation exposure, only patients 
with suspected or clinically confirmed BFR received CT 
follow-up. To exclude the bias of pure clinical follow-up 
in patients with indication for BFR, a sensitivity analysis 
was conducted considering only CT follow-up. A p value 
of < 0.05 was considered statistically significant. Statis-
tical analysis was performed using standard commercial 
software (IBM SPSS Statistics for Windows, version 21.0, 
IBM Corp.).
Ethics
Approval was granted by the local ethics committee 
(Kantonale Ethikkommission Bern, Switzerland).
Results
Patient Characteristics
During June 2003 to August 2015 a total of 183 patients 
(age range 4–81 years) who received AC after DC were 
assessed for study eligibility. A total of 25 patients (13.7%) 
did not meet the eligibility criteria; 22 of these patients 
had been lost to follow-up after AC and 3 patients had died 
before any follow-up (Fig. 2).
The baseline characteristics of the 158 eligible patients 
are summarized in Table 1. The median time between DC 
and AC was 70 days (interquartile range [IQR] 46–103.25 
days), and the median follow-up time was 2.2 years (95% 
CI 1.9–2.5 years). The patients’ mean age at the time of 
AC was 43.6 years (IQR 31.5–56 years), and 101 (63.9%) 
were male. The most common diagnosis resulting in DC 
was traumatic brain injury (TBI, n = 62, 39.2%) followed 
by cerebrovascular ischemia (CVI, n = 35, 22.2%) and 
intracerebral hemorrhage (ICH, n = 25, 15.8%). Twenty-
eight patients (17.7%) received a ventriculoperitoneal (VP) 
FIG. 2. Flowchart showing development of BFR in patients with or without antihypertensive therapy with ACEIs. 
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shunt around the time of DC. Fixation methods applied 
were titanium clamps in 7 patients (4.4%), titanium plates 
and screws in 150 patients (93.8%), and sutures in 1 pa-
tient (0.6%). Arterial hypertension was documented in 68 
patients (43%). In 22 (32.4%) of these 68 patients it was 
newly diagnosed at DC; 41 (60.3%) had documented arte-
rial hypertension in the admissions report for DC or older 
medical reports, and 5 patients (7.4%) were first recorded 
to have arterial hypertension at AC. A prescription for an 
ACEI was recorded for 57 of the hypertensive patients 
(36.1%) during their stay for AC or at later follow-up visits. 
Of the 101 patients who were not treated with an ACEI, 15 
(14.9%) had a recorded diagnosis of arterial hypertension. 
Seven (14.9%) (see Fig. 2 and Table 3) of the patients who 
were prescribed an ACEI developed BFR.
A total of 47 patients (29.7%) were clinically or radio-
logically diagnosed with BFR. Of the patients with BFR, 2 
declined revision surgery despite their neurosurgeons’ rec-
ommendations. Seven patients (4.4%) developed a wound 
infection after AC, of which none developed BFR. Two 
patients had surgical revision reasons other than BFR. One 
patient had severe dislocation of the autologous bone flap 9 
years after AC, and 1 patient had an intracranial empyema 
1 year and 8 months after AC. These patients were defined 
as having no BFR and were censored at the time of surgi-
cal revision.
Univariate Analysis
Univariate comparison showed that patients with BFR 
were younger (mean age 39.5 vs 45.3 years, p = 0.039), 
less likely to have arterial hypertension (relative risk 
[RR] 0.45, 95% CI 0.26–0.81, p = 0.005), and less likely 
to be treated with ACEIs (RR 0.31, 95% CI 0.15–0.65, p 
< 0.001), as well as less (RR 0.31) likely to have had an 
ICH (RR 0.24, 95% CI 0.06–0.91, p = 0.008) and more 
(RR 1.96) frequently subarachnoid hemorrhage (SAH, RR 
1.96, 95% CI 1.16–3.32, p = 0.046) (Table 1).
Univariate Kaplan-Meier analysis revealed that ACEI 
therapy (2-year EFP [± standard error] 83.8% ± 6.1% vs 
63.9% ± 5.6%, p = 0.02) and VP shunt placement (2-year 
EFP 86.9% ± 7.1% vs 66% ± 5.0%, p = 0.024) were as-
sociated with a lower probability of BFR (Table 2, Fig. 3).
Cox Regression Analysis
According to multiple Cox regression analysis ACEI 
treatment was associated with a lower risk for BFR (HR 
0.293, 95% CI 0.112–0.764, p = 0.012), as were VP shunt 
placement (HR 0.278, 95% CI 0.106–0.724, p = 0.009) and 
male sex (HR 0.500, 95% CI 0.258–0.969, p = 0.040) (Fig. 
4). Fragmentation of the bone flap was associated with a 
higher rate of BFR (HR 1.920, 95% CI 1.061–3.477, p = 
0.031).
TABLE 1. Baseline patient characteristics
Variable All Pts (n = 158) Pts w/o BFR (n = 111) Pts w/ BFR (n = 47) RR/Difference* (95% CI) p Value
Age in yrs, mean 43.6 ± 16.3 45.3 ± 16.0 39.5 ± 16.3 5.84 (0.31–11.38) 0.039
Male sex, n (%) 101 (63.9%) 73 (65.8%) 28 (59.6%) 0.83 (0.51–1.35) 0.474
Admission diagnosis, n (%)
 ICH 25 (15.8%) 23 (20.7%) 2 (4.3%) 0.24 (0.06–0.91) 0.008
 SAH 17 (10.8%) 8 (7.2%) 9 (19.1%) 1.96 (1.16–3.32) 0.046
 CVI 35 (22.2%) 28 (25.2%) 7 (14.9%) 0.62 (0.30–1.25) 0.209
 TBI 62 (39.2%) 41 (36.9%) 21 (44.7%) 1.25 (0.78–2.02) 0.378
 SDH 6 (3.8%) 4 (3.6%) 2 (4.3%) 1.13 (0.35–3.58) 1.000
 Cerebral infection 4 (2.5%) 2 (1.8%) 2 (4.3%) 1.71 (0.62–4.70) 0.583
 Miscellaneous 9 (5.7%) 5 (4.5%) 4 (8.5%) 0.65 (0.30–1.41) 0.452
VP shunt, n (%) 28 (17.7%) 22 (19.8%) 6 (12.8%) 0.68 (0.32–1.44) 0.365
Time from DC to AC in mos, mean 2.7 ± 1.7 2.6 ± 1.5 2.8 ± 2.1 0.13 (-0.46 to 0.72) 0.666
Medical conditions, n (%)
 Arterial hypertension 68 (43.0%) 56 (50.5%) 12 (25.5%) 0.45 (0.26–0.81) 0.005
 Diabetes mellitus 10 (6.3%) 8 (7.2%) 2 (4.3%) 0.66 (0.19–2.33) 0.724
Antihypertensive therapy, n (%)
 ACEI 57 (36.1%) 50 (45%) 7 (14.9%) 0.31 (0.15–0.65) <0.001
 Other antihypertensive drugs 46 (29.1%) 37 (33.3%) 9 (19.1%) 0.58 (0.30–1.09) 0.086
Nicotine consumption 36 (22.8%) 25 (22.5%) 11 (23.4%) 1.02 (0.79–1.3) 1.000
Size in cm2, mean 110.1 ± 22.4 112.5 ± 2.1 104.9 ± 2.6 7.6 (-0.10 to 15.35) 0.053
≥2 fragments, n (%)† 43 (29.3%) 26 (25.5%) 17 (37.8%) 1.47 (0.90–2.39) 0.096
Pts = patients; SDH = subdural hemorrhage.
Continuous values are depicted as means ± SD, discrete values as their absolute number of observations (n) and the percentage of the respective group; p values are 
from 2-sample t-tests for continuous variables and Fisher’s exact tests for categorical variables.
* The relative risk is presented for categorical data and the difference in the means for continuous data.
† Total n = 147, with BFR = 45, without BFR = 102.
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A sensitivity analysis considering only CT follow-up 
and omitting clinical follow-up data continued to show a 
reduced risk for BFR in patients with ACEIs (HR 0.299, p 
= 0.01), as well as an elevated risk in patients with multiple 
fragmentation of the bone flap (HR 1.794, p = 0.042).
Discussion
Definition of Bone Flap Resorption
As of this writing, there has been no consensus on a def-
inition for the term “bone flap resorption” (BFR). Ewald et 
al.9 and Dünisch et al.8 defined a type II bone flap necrosis 
as a circumscribed or complete lysis of both the tabula in-
terna and the tabula externa with the requirement of sur-
gical revision. Stieglitz et al.35 categorized BFR using a 
scoring system, with major resorption requiring a second 
surgery. We limited the definition of BFR to the indication 
for revision surgery. In our study, 47 patients (29.7%) were 
diagnosed with BFR, which appears to be in line with 
rates previously reported in the literature (Table 3).
Arterial Hypertension and BFR
Arterial hypertension was a frequent comorbidity in 
our study (affecting 43% of patients, with 97.1% of these 
hypertensive patients receiving antihypertensive medica-
tion) because hypertensive patients have a severely height-
ened risk for cerebrovascular incidents such as CVI or 
ICH.1,23 Analysis of baseline characteristics showed that a 
majority of the patients with BFR were admitted with TBI 
(n = 21, 44.7%) and SAH (n = 9, 19.1%), and that the major-
ity of patients without BFR were admitted due to TBI (n = 
41, 36.9%) or CVI (n = 28, 25.2%). More patients suffered 
from ICH than from SAH (n = 25, 15.8% vs n = 17, 10.8%). 
In a prospective study involving elderly females, Cappuc-
cio et al.6 showed that hypertension is associated with an 
abnormal calcium metabolism. It leads to increased uri-
nary calcium excretion, secondary activation of the para-
thyroid gland, and increased calcium mobilization from 
bone. In our study, 68 patients had a diagnosis of arterial 
hypertension, and 12 (17.6%) of these patients developed 
BFR. Sixty-six (97.1%) of the 68 patients with arterial hy-
pertension received antihypertensive medication, and 57 
(83.8%) of these 68 received an ACEI.
However, we cannot assume that the possible benefit 
of ACEI therapy with respect to development of BFR 
is based solely on normalization of blood pressure. Ac-
cording to the literature, not all antihypertensive drugs 
beneficially affect osteoporosis and bone mineralization, 
as they differ in the way they work to reduce blood pres-
sure.19,38 Previous findings suggest a beneficial effect of 
TABLE 2. Results of univariate Kaplan-Meier analysis with log-
rank test
Variable
2-yr EFP* 
(%)
mTTE 
(yrs)
mTTE, 
95% CI
p 
Value
Age in yrs 0.632
 0–20 55.6 ± 11.7 4.2 0.0–8.8
 21–40 65.7 ± 8.5 3.8 2.1–5.5
 41–60 74.9 ± 6.6 3.7 2.4–5.0
 61–80 79.7 ± 9.1 NR NR
Sex 0.075
 Male 74.1 ± 5.1 3.9 3.5–4.4
 Female 63.4 ± 7.6 2.7 2.3–3.1
VP shunt 0.024
 Yes 86.9 ± 7.1 4.2 NR
 No 66.0 ± 5.0 3.6 2.5–4.7
Time from DC to AC in mos 0.551
 ≤2 72.9 ± 6.7 4.2 2.0–6.4
 2.1–4 64.0 ± 6.8 3.4 2.1–4.8
 4.1–6 72.9 ± 13.5 3.9 NR
 >6.1 90.0 ± 9.5 3.6 0.0–8.1
ACEI 0.02
 Yes 83.8 ± 6.1 NR NR
 No 63.9 ± 5.6 3.6 2.4–4.9
Bone flap size in cm2 0.52
 ≤70 38.1 ± 19.9 1.9 0.1–3.7
 71–90 90.9 ± 8.7 3.7 2.6–4.8
 91–110 68.8 ± 9.2 3.9 2.5–5.4
 ≥110 66.3 ± 6.0 3.4 NR
Fragments 0.488
 ≥2 65.3 ± 7.8 5.5 1.8–9.2
 <2 69.1 ± 5.6 3.8 3.6–4.8
2-yr EFP = 2-year event free probability; mTTE = median time to event; NR = 
not reached.
* Presented with standard error.
FIG. 3. Kaplan-Meier analysis of patients with and without ACEI treat-
ment and number of patients at risk after each time interval. Tick marks 
indicate censored events.
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ACEI therapy on bone preservation by direct alteration of 
the RAAS.12,16
The Renin-Angiotensin-Aldosterone System and Bone 
Metabolism
In recent years, multiple studies conducted in orthope-
dic, osteoporosis, and endocrinology research have associ-
ated ACEIs with a beneficial effect on bone preservation 
and bone healing.26,28,31,34,39 In animal studies, activation 
of the renin-angiotensin-aldosterone system (RAAS), a 
system that regulates blood volume and pressure through 
multiple hormones and enzymes systemically and lo-
cally, seems to induce osteoporosis,2 which was attenu-
ated by ACEI administration.34 Furthermore, it has been 
possible to increase bone resorption and decrease bone 
mineral density by administration of angiotensin II in a 
mouse model,2 while local injection of ACEI into the area 
of tibial fractures has resulted in improved bone healing 
in a rat model.39 In human studies, a 1-hour infusion of 
angiotensin II, alone or in combination with human para-
thyroid hormone (PTH), has been shown to inhibit RAAS 
and calcium metabolism,13 whereas ACEI therapy was as-
sociated with an increased bone mass26 and a decreased 
fracture risk.13,28,31,37
Previous studies have explained these effects by show-
ing that angiotensin II indirectly stimulates osteoclast for-
mation,2 leads to decreased ionic calcium and increased 
PTH levels,13 and directly affects local tissue-specific 
RAAS also found within bone tissue.12,16 Administration of 
an ACEI prevents the enzymatic conversion of angiotensin 
I into angiotensin II, thus preventing the catabolic effect of 
angiotensin II, thus resulting in decreased bone resorption. 
Furthermore, ACEIs have been shown to increase bone 
mass in hypertensive women with a specific polymorphism 
of the ACE gene due to a stronger inhibitory effect by the 
ACEI and further decrease of angiotensin II levels.26
Of the 68 (Table 1) hypertensive patients in our study, 
57 (84%) were following a regimen of ACEI therapy. We 
identified these patients as having a lower rate of BFR.
Our results are in line with findings in the literature, 
showing how ACEIs can positively affect osteogenesis by 
alteration of the RAAS in hypertensive patients. This im-
plicates a potential preventive measure against BFR, which 
could be offered to patients undergoing AC. However, our 
investigation was limited to a prescription for an ACEI in 
patients with a known arterial hypertension. Their effects 
on BFR in normotensive patients therefore remain unclear. 
For future studies, we recommend considering all drugs 
acting on the RAAS and their potential effects on bone 
metabolism, as well as investigating the effects of ACEIs 
on BFR in normotensive patients.
Sex, VP Shunts, and Bone Fragmentation
In our analysis, we found male sex to be associated with 
lower BFR rates. Previous studies did not identify patient 
sex as a risk factor for BFR in pediatric and mixed co-
horts.4,8 However, prior studies suggest an altered bone 
metabolism in postmenopausal women due to changes in 
estrogen levels affecting bone metabolism (e.g., resulting 
in lower bone mineral density11 or complications in the 
healing of fractures such as clavicular or femoral neck 
fractures24,29).
Additionally, our analysis found VP shunt placement to 
be associated with lower BFR rates. In previous studies, 
shunt-dependent hydrocephalus has been reported to be a 
risk factor for BFR,4,22,25 the reason for this however is not 
established. Overall, the impact of hydrocephalus and VP 
shunts on BFR rates remains unclear.
Increasing fragmentation of the bone flap was associ-
ated with higher BFR rates, confirming results found in 
previous reports.5,8,21,33 It has been theorized that fragmen-
tation leads to a nutritional deficit of the bone flap8 and 
disturbance of later angiogenesis and the survival of the 
graft.5
Limitations
Given that this was a single-institution study, our cohort 
size and event numbers were limited. Because our institu-
tional protocol only required a 6-week postoperative fol-
FIG. 4. Results and plot of hazard ratios from a multiple Cox regression analysis on a logarithmic scale.
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low-up visit, a minority of patients did not receive further 
follow-up evaluations. This may be because they or their 
caregivers did not consider additional follow-up necessary, 
or it may be due to other unknown reasons. Intraopera-
tive placement of multiple perforations in the bone flap and 
the fixation method were not standardized. Neither were 
duration, dosage, or combination of drug therapy. In the 
literature an elevated risk for osteoporosis and fractures 
have been found to be associated with many medical and 
metabolic factors (e.g., increasing age, steroid therapy, 
hormonal factors including menopause, amenorrhea, hy-
perthyroidism, hyperadrenocorticism and hypogonadism) 
as well as lifestyle factors, such as low physical activity, 
nicotine or alcohol consumption, low body weight, or low 
dietary calcium and vitamin D intake.7 In recent years in-
terest has risen as to the use of osteoinductive factors such 
as bone morphogenetic proteins (BMPs), which have been 
applied in orthopedic surgery to improve bone healing and 
enhance spinal fusion.20 However, to our knowledge BMPs 
have not been applied in autologous cranioplasty. Apart 
from patient age and nicotine consumption, which were 
not significant in our analysis, we did not assess any of 
these factors.
Conclusions
ACEI therapy appears to decrease the risk of BFR after 
AC in hypertensive patients (76% relative risk reduction). 
This finding is in line with previous reports on the posi-
tive influence of ACEIs on bone healing and preservation. 
ACEI therapy may thus be considered as the antihyperten-
sive treatment of choice in patients who have undergone 
AC. Further analysis of the association between ACEI 
and BFR development is needed and will be evaluated in 
the Swiss Prospective Autologous Bone Flap Resorption 
Study (SPARS), a multicenter prospective trial.36
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